JPRN-UMIN000004359招募中未知
A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancer - A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancer
Shinshu University School of Medicine, Surgery0 个研究点目标入组 33 人开始时间: 2010年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Interstitial pneumonia heart failure ascites and edema Infection diabetes mellitus Allergy of the drugs
研究者
相似试验
招募中
1 期
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.MedDRA version: 20.0Level: PTClassification code: 10018337Term: Glioblastoma multiforme Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864glioblastomaCTIS2023-508278-26-01Z Brussel18
已完成
不适用
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed dendritic cells for patients with advanced high-grade salivary gland tumor followed by standard therpies.Salivary gland tumorJPRN-UMIN000024669Chiba University Hospital6
已完成
1 期
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with high-grade salivary grand tumor followed by standard therpies.High-grade salivary grand tumorJPRN-UMIN000011509Department of Otorynolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University9
已完成
3 期
A phase III randomized trial of adjuvant therapy with irsogladine maleate for the patient with completely resected non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000005901Japanese Northern East Area Thoracic Surgery Study Group (JNETS)310
进行中（未招募）
不适用
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin